S
Sensei Biotherapeutics, Inc. (SNSE)
NCM – Real Time Price. Currency in USD
21.00
+0.27 (1.30%)
At close: May 12, 2026, 4:00 PM EDT
22.00
+1.00 (4.76%)
Pre-market: May 13, 2026, 4:06 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
21.00
+0.27 (1.30%)
At close: May 12, 2026, 4:00 PM EDT
22.00
+1.00 (4.76%)
Pre-market: May 13, 2026, 4:06 AM EDT
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
| Name | Position |
|---|---|
| Mr. Anand Parikh Esq., J.D. | COO & Director |
| Mr. Christopher W. Gerry J.D. | President, General Counsel, Secretary & Director |
| Mr. Josiah Craver CPA | Senior VP of Finance, Principal Financial Officer & Principal Accounting Officer |
| Ms. Lora Pike | Vice President of Investor Relations & Communications |
| Date | Type | Document |
|---|---|---|
| 2026-04-28 | S-3 | d133316ds3.htm |
| 2026-04-27 | DEFA14A | d79730ddefa14a.htm |
| 2026-04-16 | 8-K | d85136d8k.htm |
| 2026-04-15 | 8-K/A | d40329d8ka.htm |
| 2026-03-30 | 8-K | d118677d8k.htm |
| 2026-03-30 | 10-K | snse-20251231.htm |
| 2026-03-04 | D | |
| 2026-02-18 | 8-K | d112826d8k.htm |
| 2026-02-13 | 8-K | d82134d8k.htm |
| 2025-12-23 | 8-K | d68669d8k.htm |